NOTTINGHAM, UK – 29 June, 2021 – Life Science Newswire – Sygnature Discovery, the leading provider of integrated drug discovery services, has received a significant investment from Five Arrows Principal Investments, the European corporate private equity arm of Rothschild & Co. Financial details have not been disclosed.
Sygnature Discovery is a leading independent integrated drug discovery and non-clinical services company. Private equity-backed since 2017, the company operates fully enabled research facilities in Nottingham and Alderley Park, UK, housing nearly 400 research scientists (over 80% of whom hold a PhD), and has an office presence in Cambridge, MA, and South San Francisco, CA, in the US.
|
Five Arrows Principal Investments (Five Arrows) is part of the European private equity arm of Rothschild & Co’s Merchant Banking business. Merchant Banking manages over €16.2bn globally which includes approximately €4.1 billion dedicated to corporate private equity, as well as a series of funds dedicated to senior and junior credits, primary and secondary fund investing and co-investments, with offices in Paris, London, New York, Los Angeles and Luxembourg.
Five Arrows focuses on investing in middle-market companies with highly defensible market positions; strong management teams; business models with high visibility of organic unit volume growth and strong free cash flow conversion; and multiple operational levers that can be used to unlock latent value. Sectors are limited to data and software, technology-enabled business services and healthcare.
For more information: www.rothschildandco.com/en/merchant-banking/corporate-private-equity
Anders Lindstrom
Director of Marketing
Sygnature Discovery
Phone: +44 (0)115 941 5401
Email: A.Lindstrom@sygnaturediscovery.com